Lasa Supergenerics Ltd (NSE: LASA, BSE: 540702) is a Ratnagiri, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹21 Cr, it ranks #4,394 by market cap among the 6,197 Indian listed companies on FinBizNet, and #57 of 63 in Pharmaceuticals. At ₹4.22 (as of 16 Nov 2026), the share price is 65.0% below its 52-week high of ₹12.04 and 0.0% above its 52-week low of ₹4.22. The share price is down 63.3% over one year and down 43.9% over three months.
| Current Price | ₹4.22 |
|---|---|
| Market Cap | ₹21 Cr |
| NSE Symbol | LASA |
| BSE Code | 540702 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -51.14% |
| Return on Assets | -9.82% |
| 52-Week Range | ₹4.22 – ₹12.04 |
| 1-Year Price Change | -63.3% |
| 3-Month Price Change | -43.9% |
| Beta (1Y) | 1.07 |
| Dividend Yield | 5.92% |
| Headquarters | Ratnagiri, Maharashtra |
| Website | lasalabs.com |
| Revenue | ₹0 Cr |
|---|---|
| Net Profit | ₹-2 Cr |
| Net Margin | -18400.0% |
| EPS (Basic) | ₹-0.37 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Lasa Supergenerics Ltd reported revenue of ₹0 Cr in Q2 FY27, down 99.7% from ₹3 Cr in Q2 FY26 and down 99.2% from ₹1 Cr in Q1 FY27. It posted a net loss of ₹2 Cr for the quarter, against a net loss of ₹6 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹-0 Cr (Q4 FY26) to ₹39 Cr (Q4 FY25). The company reported a net loss in 7 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹0 Cr | −₹2 Cr | −18400.0% |
| Q1 FY27 | ₹1 Cr | −₹4 Cr | −291.1% |
| Q4 FY26 | ₹-0 Cr | −₹4 Cr | — |
| Q3 FY26 | ₹2 Cr | −₹3 Cr | −115.9% |
| Q2 FY26 | ₹3 Cr | −₹6 Cr | −204.2% |
| Q1 FY26 | ₹20 Cr | −₹21 Cr | −105.5% |
| Q4 FY25 | ₹39 Cr | −₹14 Cr | −36.5% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 53.65% of Lasa Supergenerics Ltd's shares as of Sept 2026, unchanged from Sept 2025.
Lasa Supergenerics Ltd made one exchange disclosure in the Corporate Insolvency Resolution Process (CIRP) category, on 4 Dec 2024. The filings do not mention a Committee of Creditors or a Resolution Professional. Disclosures in this category can concern a petition, an appeal, a subsidiary or another company. The most recent specific filing, dated 4 Dec 2024, reads: "In continuation of our annoucement dated 13.11.2024 , dismissal of insolvency application as withdraw from Financial Creditor , kindly find attached order for the same as uploaded by NCLT."
Taken from the company's own stock exchange filings. FinBizNet does not infer the current status of any proceeding.
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
1. Active Pharmaceutical Ingredients (API)-This segments engages in the research, manufacture, and marketing of animal and human healthcare products.
1. Active Pharmaceutical Ingredients (API)-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Lasa Supergenerics Ltd | ₹21 Cr | n/m | -51.14% | ₹0 Cr | -63.3% |
Listed by market capitalisation. Ratios are shown for context only.
Lasa Supergenerics Ltd is trading at ₹4.22, with a market capitalisation of ₹21 Cr.
Lasa Supergenerics Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Lasa Supergenerics Ltd has a return on equity of -51.14%.
Lasa Supergenerics Ltd is listed on the NSE under the symbol LASA and on the BSE under the scrip code 540702.
Lasa Supergenerics Ltd's share price is down 63.3% over one year and down 43.9% over three months. Its 52-week range is ₹4.22 to ₹12.04.
In Q2 FY27, Lasa Supergenerics Ltd reported revenue of ₹0 Cr and net profit of ₹-2 Cr, with basic EPS of ₹-0.37 (standalone, parsed from the company's exchange filing).
Lasa Supergenerics Ltd reported revenue of ₹0 Cr in Q2 FY27, down 99.7% from ₹3 Cr in Q2 FY26 and down 99.2% from ₹1 Cr in Q1 FY27.
Promoters held 53.65% of Lasa Supergenerics Ltd's shares as of Sept 2026, unchanged from Sept 2025.
Lasa Supergenerics Ltd made one exchange disclosure in the Corporate Insolvency Resolution Process (CIRP) category, on 4 Dec 2024. The filings do not mention a Committee of Creditors or a Resolution Professional. Disclosures in this category can concern a petition, an appeal, a subsidiary or another company. The most recent specific filing, dated 4 Dec 2024, reads: "In continuation of our annoucement dated 13.11.2024 , dismissal of insolvency application as withdraw from Financial Creditor , kindly find attached order for the same as uploaded by NCLT."
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.